Sp383
A LOOK AHEAD: HEAD-TO-HEAD TRIALS, COMBINATION BIOLOGICS, DE-ESCALATION, AND NEW THERAPIES
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring. This session will review the role of historic and emerging biologics for management of CD and UC, examine comparative efficacy and safety and define the concepts of therapeutic drug monitoring, combinational biologic therapy, and rational de-escalation.
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring. This session will review the role of historic and emerging biologics for management of CD and UC, examine comparative efficacy and safety and define the concepts of therapeutic drug monitoring, combinational biologic therapy, and rational de-escalation.
Presenter
University of Chicago Division of the Biological Sciences
Tracks
Related Products
BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS
BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
THE IMPACT OF COVID-19 ON EARLY LIFE GUT MICROBIOME: IMPLICATIONS FROM TWO INDEPENDENT MOTHER-BABY DYAD COHORTS IN THE GREATER BAY AREA OF CHINA
BACKGROUND: Through shotgun metagenomic sequencing, we identified the depletion of probiotic species_ Lactobacillus acidophilus_ in stools of mice with non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC)…
PANEL DISCUSSION
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…